Spark Therapeutics Inc (ONCE) Receives $69.50 Consensus Price Target from Brokerages

Shares of Spark Therapeutics Inc (NASDAQ:ONCE) have been assigned a consensus rating of “Hold” from the twenty-three brokerages that are covering the company, Marketbeat reports. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have assigned a buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $69.50.

A number of research analysts have recently weighed in on the company. Credit Suisse Group lifted their price target on Spark Therapeutics from $75.00 to $98.00 and gave the company an “outperform” rating in a report on Monday, July 9th. Royal Bank of Canada downgraded Spark Therapeutics from an “outperform” rating to a “sector perform” rating and set a $100.00 price target on the stock. in a report on Thursday, July 19th. Cantor Fitzgerald set a $103.00 price target on Spark Therapeutics and gave the company a “buy” rating in a report on Monday, July 16th. ValuEngine downgraded Spark Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 24th. Finally, Raymond James set a $82.00 price target on Spark Therapeutics and gave the company a “buy” rating in a report on Wednesday, August 8th.

Shares of ONCE stock traded down $1.85 on Thursday, reaching $45.29. 1,046,472 shares of the company’s stock traded hands, compared to its average volume of 486,316. Spark Therapeutics has a 12-month low of $41.06 and a 12-month high of $96.59.

Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings results on Tuesday, August 7th. The biotechnology company reported ($0.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.34). Spark Therapeutics had a negative net margin of 185.46% and a negative return on equity of 17.33%. The business had revenue of $25.19 million for the quarter, compared to analysts’ expectations of $29.44 million. On average, equities research analysts anticipate that Spark Therapeutics will post -1.44 EPS for the current year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Aperio Group LLC boosted its position in Spark Therapeutics by 23.5% during the second quarter. Aperio Group LLC now owns 5,543 shares of the biotechnology company’s stock valued at $459,000 after purchasing an additional 1,056 shares during the last quarter. Tocqueville Asset Management L.P. boosted its position in Spark Therapeutics by 2.7% during the second quarter. Tocqueville Asset Management L.P. now owns 41,225 shares of the biotechnology company’s stock valued at $3,412,000 after purchasing an additional 1,075 shares during the last quarter. Amalgamated Bank boosted its position in Spark Therapeutics by 29.7% during the second quarter. Amalgamated Bank now owns 4,799 shares of the biotechnology company’s stock valued at $397,000 after purchasing an additional 1,100 shares during the last quarter. Smith Asset Management Group LP boosted its position in Spark Therapeutics by 39.6% during the third quarter. Smith Asset Management Group LP now owns 3,950 shares of the biotechnology company’s stock valued at $215,000 after purchasing an additional 1,120 shares during the last quarter. Finally, Capital Fund Management S.A. boosted its position in Spark Therapeutics by 8.1% during the second quarter. Capital Fund Management S.A. now owns 15,379 shares of the biotechnology company’s stock valued at $1,273,000 after purchasing an additional 1,152 shares during the last quarter.

About Spark Therapeutics

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.

Read More: What are the risks of holding treasury bonds?

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply